REVIVA PHARMACEUTICALS HOLDI (RVPH)

US76152G1004 - Common Stock

1.25  -0.07 (-5.3%)

After market: 1.19 -0.06 (-4.8%)

Fundamental Rating

0

Taking everything into account, RVPH scores 0 out of 10 in our fundamental rating. RVPH was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RVPH have multiple concerns. RVPH has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year RVPH has reported negative net income.
RVPH had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: RVPH reported negative net income in multiple years.
In the past 5 years RVPH always reported negative operating cash flow.

1.2 Ratios

RVPH has a worse Return On Assets (-440.96%) than 95.31% of its industry peers.
Industry RankSector Rank
ROA -440.96%
ROE N/A
ROIC N/A
ROA(3y)-51.59%
ROA(5y)N/A
ROE(3y)-75.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RVPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

RVPH has more shares outstanding than it did 1 year ago.
There is no outstanding debt for RVPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

RVPH has an Altman-Z score of -40.20. This is a bad value and indicates that RVPH is not financially healthy and even has some risk of bankruptcy.
RVPH's Altman-Z score of -40.20 is on the low side compared to the rest of the industry. RVPH is outperformed by 92.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -40.2
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

RVPH has a Current Ratio of 0.52. This is a bad value and indicates that RVPH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.52, RVPH is doing worse than 94.79% of the companies in the same industry.
RVPH has a Quick Ratio of 0.52. This is a bad value and indicates that RVPH is not financially healthy enough and could expect problems in meeting its short term obligations.
RVPH has a Quick ratio of 0.52. This is amonst the worse of the industry: RVPH underperforms 92.71% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.52

1

3. Growth

3.1 Past

RVPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.80%.
EPS 1Y (TTM)7.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RVPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.40% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.01%
EPS Next 2Y9.56%
EPS Next 3Y10.13%
EPS Next 5Y18.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.56%
EPS Next 3Y10.13%

0

5. Dividend

5.1 Amount

No dividends for RVPH!.
Industry RankSector Rank
Dividend Yield N/A

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (11/13/2024, 5:24:38 PM)

After market: 1.19 -0.06 (-4.8%)

1.25

-0.07 (-5.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap41.80M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -440.96%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.52
Quick Ratio 0.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)7.8%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-33.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y